Drug Target Review – Publications

Issue #3 2021

The next issue of Drug Target Review goes to press on 9 September 2021 and will feature:

• In-Depth Focuses on: Assays; Synthetic Biology; Vaccine Development 
• Plus articles on Informatics, Organoids and Neuroscience
• And much more…

To receive our latest journal, you can secure your free print and/or digital copy here.

Latest issue

Issue #2 2021

Drug Target Review – Issue 2 2021

This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being…

By Drug Target Review

Issue #2 2021

Drug Target Review Antibodies ebook 2021

Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can…

By Drug Target Review

Issue #2 2021

Drug Target Review Cell & Gene Therapy ebook 2021

In this ebook, discover how organoids can be used in regenerative medicine and how a novel AAV vector for gene…

By Drug Target Review

Issue #2 2021

Drug Target Review Screening ebook 2021

This ebook has articles on the use of screening to identify COVID-19 drugs and how assessing compound activity could accelerate…

By Drug Target Review

Issue #2 2021

Drug Target Review Stem Cells ebook 2021

Included in this ebook are articles on stem cell-derived liver organoids and pluripotent cell-derived endothelial cells.

By Drug Target Review

Issue #2 2021

Digital revolution – not evolution – is the route to…

With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19…

By Richard Goodwin (AstraZeneca)

Issue #2 2021

How to mix the best anti-SARS-CoV-2 cocktail

Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to…

By Dr Zhiqiang Ku (University of Texas Health Science Center at Houston)

Issue #2 2021

Better therapeutic antibodies by design

The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range…

By Aparajita Dubey (CRAMbridge)

Issue #2 2021

Under the microscope: Exploring phage display technologies for drug discovery…

With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead…

By IRBM Science park

Issue #2 2021

Application note: Improving and simplifying the design of knock-in experiments…

Genome editing technologies have given investigators the power to unlock a variety of new applications and experimental approaches. While gene…

By Thermo Fisher Scientific

Issue #2 2021

Application note: Effectiveness of CRISPR‑Cas9 using pools of synthetic crRNAs…

Chemical synthesis of guide RNAs for CRISPR-Cas9 gene editing enables accurate and rapid production of CRISPR libraries and screening in…

By Horizon Discovery

Issue #2 2021

The potential of epigenomic medicine in cardiology

Advances in genomic medicine are playing an increasingly important role in the field of cardiology. Better analysis and understanding of…

By Professor John Giannios (Learna)

Issue #2 2021

The benefits of lab automation in life sciences

While researchers conduct their studies, constraints such as time can impact their work. Dr Ian Holland from the University of…

By Dr Ian Holland (University of Edinburgh)

Issue #2 2021

The use of biophysical methods in the hit-to-lead process

Optimisation of a hit towards a lead happens in a variety of ways, as a lead needs to meet various…

By Dr Thomas Schubert (2bind)

Issue #2 2021

Why some screening hits are a PAIN

A major challenge during high-throughput and fragment screening is the potential for identifying ‘frequent hitters’ – compounds that affect unrelated…

By Dr Matthew Lloyd (University of Bath)

Issue #2 2021

Assessing compound activity to accelerate drug discovery

In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules…

By Victoria Rees (Drug Target Review)

Issue #2 2021

Screening for COVID-19 drugs

With the COVID-19 pandemic ongoing, new therapeutic drugs to combat SARS-CoV-2 are still required. In this article, Professor Arvind Patel…

By Professor Arvind Patel (University of Glasgow)

Issue #2 2021

Targeting phosphodiesterase 3A: discovery of a promising cancer therapy

A new promising sarcoma target, phosphodiesterase 3A (PDE3A), and drugs targeting it have been identified by researchers at the University…

By Dr Harri Sihto (University of Helsinki), Dr Katja Ivanitskiy (Sartar Therapeutics), Professor Olli Kallioniemi (Sartar Therapeutics)

Issue #2 2021

Covalent fragment screening in cell-based phenotypic models of disease: a…

The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly,…

By Dr Andrew Powell (GlaxoSmithKline), Dr David House (GlaxoSmithKline), Dr Jacob Bush (GlaxoSmithKline), Dr Katrin Rittinger (The Francis Crick Institute), Dr Simon Boulton (The Francis Crick Institute)

Issue #2 2021

Application note: Pushing the boundaries in pharmaceutical hit discovery with…

We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results…

By Creoptix

Issue #2 2021

Using cholangiocyte organoids to regenerate human bile ducts

A team of researchers has shown that injection of cholangiocyte organoids in human livers ex vivo can repair the organs’…

By Dr Fotios Sampaziotis (University of Cambridge)

Issue #2 2021

Novel vectors for more efficient and less risky ocular gene…

Inherited blindness is the leading cause of vision loss in the working populations. Recently, the first gene therapy for the…

By Professor Stylianos Michalakis (Ludwig Maximilian University)

Issue #2 2021

Making cell culture models more physiologically relevant

A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived…

By Robert Skolik (University of Louisville)

Issue #2 2021

Drug development in stem cell-derived liver organoid models

To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested…

By Dr Takanori Takebe (Cincinnati Children’s Hospital)

Issue #2 2021

Transcriptional reprogramming rescues vascular fate of misidentified pluripotent cell‑derived epithelial…

A team of scientists has found that a type of cell derived from human stem cells and widely used for…

By Dr Raphaël Lis (Weill Cornell Medicine)

Issue #2 2021

Product hub: Octet® R series systems

Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or…

By Sartorius AG

Past Issues

Issue #1 2021

Drug Target Review – Issue 1 2021

Issue #4 2020

Drug Target Review – Issue 4 2020

Issue #3 2020

Drug Target Review – Issue 3 2020

Issue #2 2020

Drug Target Review – Issue 2 2020

Issue #1 2020

Drug Target Review – Issue 1 2020

Issue #4 2019

Drug Target Review – Issue 4 2019

Issue #3 2019

Drug Target Review – Issue 3 2019

Issue #2 2019

Drug Target Review – Issue 2 2019

Issue #1 2019

Drug Target Review – Issue 1 2019

Issue #4 2018

Drug Target Review – Issue 4 2018

Issue #3 2018

Drug Target Review – Issue 3 2018

Issue #2 2018

Drug Target Review – Issue #2 2018

Issue #1 2018

Drug Target Review – Issue #1 2018

Issue #4 2017

Drug Target Review – Issue #4 2017

Issue #3 2017

Drug Target Review – Issue #3 2017

 

Supplements & Special Editions

Issue #1 2021

Drug Target Review Vaccine Development ebook 2021

Issue #1 2021

Drug Target Review Antibodies ebook 2021

Issue #1 2021

Drug Target Review Assays ebook 2021

Issue #4 2020

Upstream Bioprocessing In-Depth Focus 2020

Issue #4 2020

COVID-19 In-Depth Focus 2020

Issue #4 2020

Screening In-Depth Focus 2020

Issue #3 2020

NGS In-Depth Focus 2020

Issue #3 2020

Assays In-Depth Focus 2020

Issue #3 2020

Targets In-Depth Focus 2020

Issue #3 2020

Antibodies In-Depth Focus 2020

Issue #2 2020

Stem Cells In-Depth Focus 2020

Issue #2 2020

Imaging In-Depth Focus 2020

Issue #2 2020

Immuno-oncology In-Depth Focus 2020

Issue #2 2020

Screening In-Depth Focus 2020

Issue #1 2020

Lab Automation In-Depth Focus 2020